Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils

Molecular Psychiatry

Volumn 8, Issue 2, 2003, Pages 195-208

  De Ferrari, G V ^a   Chacon M A ^a   Barria M I ^a   Garrido, J L ^a   Godoy, J A ^a   Olivares, G ^a   Reyes, A E ^a   Alvarez, A ^a   Bronfman, M ^a   Inestrosa, N C ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Alzheimer's disease; Amyloid peptide; Behavior; Lithium; Neurodegeneration; Wnt signaling

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; PROTEIN KINASE C INHIBITOR; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CELL SURVIVAL; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DRUG EFFECT; ENZYME INHIBITION; FETUS; HIPPOCAMPUS; LEARNING; MAZE TEST; MITOSIS; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; SIGNAL TRANSDUCTION; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; BETA CATENIN; CELL DEATH; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOSKELETAL PROTEINS; HUMANS; ISOENZYMES; KIDNEY; LITHIUM; MEMORY DISORDERS; MICE; NERVE DEGENERATION; NEURONS; PROTEIN KINASE C; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSFECTION; WNT PROTEINS;

EID: 0037220599     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001208     Document Type: Article

References (86)

1. Selkoe DJ. The origins of Alzheimer disease: A is for amyloid. JAMA 2000; 283: 1615-1617.
2. Mandelkow E-M, Mandelkow E. τ in Alzheimer's disease. Trends Cell Biol 1998; 8: 425-427.
3. Busciglio J, Lorenzo A, Yeh J, Yankner BA. β-amyloid fibrils induce τ phosphorylation and loss of microtubule binding. Neuron 1995; 14: 879-888.
4. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K. Tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity. Proc Natl Acad Sci USA 1993; 90: 7789-7793.
5. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M et al. Activation of τ protein kinase I/glycogen synthase kinase-3β by amyloid β-peptide (25-35) enhances phosphorylation of τ in hippocampal neurons. Neurosci Res 1998; 31: 317-323.
6. Siegfried E, Chou TB, Perrimon N. Wingless signaling acts through zeste-white 3, the Drosophila homolog of glycogen synthase kinase-3, to regulate engrailed and establish cell fate. Cell 1992; 71: 1167-1179.
7. Cook D, Fry MJ, Hughes K, Sumathipala R, Woodget JR, Dale TC. Wingless inactivates glycogen synthase kinase-3 via an intracellular signaling which involves a protein kinase C. EMBO J 1996; 15: 4526-4536.
8. Chen RH, Ding WV, McCormick F. Wnt signaling to β-catenin involves two interactive components. Glycogen synthase kinase-3β inhibition and activation of protein kinase C. J Biol Chem 2000; 275: 17 894-17 899.
9. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998; 14: 59-88.
10. Kuhl M, Sheldahl LC, Park M, Miller JL, Moon RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet 2000; 16: 279-283.
11. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 1443-1454.
12. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
13. Nusse R, Varmus HE. Wnt genes. Cell 1992; 69: 1073-1087.
14. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851.
15. Wassink TH, Piven J, Vieland VJ, Huang J, Swiderski E, Pietila J et al. Evidence supporting WNT2 as an autism susceptibility gene. Am J Med Genet 2001; 105: 406-413.
16. Andres C. Molecular genetics and animal models in autistic disorder. Brain Res Bull 2002; 57: 109-119.
17. Cotter D, Kerwin R, al-Sarraji S, Brion JP, Chadwich A, Lovestone S et al. Abnormalities of Wnt signalling in schizophrenia - evidence for neurodevelopmental abnormality. Neuroreport 1998; 9: 1379-1383.
18. Miyaoka T, Seno T, Ishino H. Increased expression of Wnt-1 in schizophrenic brains. Schizophr Res 1999; 38: 1-6.
19. De Ferrari GV, Inestrosa NC. Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev 2000; 33: 1-12.
20. Anderton BH, Dayanandan R, Killick R, Lovestone S. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? Mol Med Today 2000; 6: 54-59.
21. Zhou J, Liyanage U, Medina M, Ho C, Simmons AD, Lovett M et al. Presenilin 1 interaction in the brain with a novel member of the Armadillo family. NeuroReport 1997; 8: 2085-2090.
22. Yu G, Chen F, Levesque G, Nishimura M, Zhang DM, Levesque L et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains β-catenin. J Biol Chem 1998; 273: 16 470-16 475.
23. Tesco G, Kim TW, Diehlmann A, Beyreuther K, Tanzi RE. Abrogation of the presenilin 1/β-catenin interaction and preservation of the heterodimeric presenilin 1 complex following caspase activation. J Biol Chem 1998; 273: 33 909-33 914.
24. Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 1998; 395: 698-702.
25. Nishimura M, Yu G, Levesque G, Zhang DM, Ruel L, Chen F et al. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of β-catenin, a component of the presenilin protein. Nat Med 1999; 5: 164-169.
26. Kawamura Y, Kikuchi A, Takada R, Takada S, Sudoh S, Shibamoto S et al. Inhibitory effect of a presenilin 1 mutation on the Wnt signalling pathway by enhancement of β-catenin phosphorylation. Eur J Biochem 2001; 268: 3036-3041.
27. Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K et al. Presenilin 1 associates with glycogen synthase kinase-3β and its substrate τ. Proc Natl Acad Sci USA 1998; 95: 9637-9641.
28. Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS et al. Presenilin 1 facilitates the constitutive turnover of β-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the β-catenin-signaling pathway. J Neurosci 1999; 19: 4229-4237.
29. Tesco G, Tanzi RE. GSK3β forms a tetrameric complex with endogenous PS1-CTF/NTF and β-catenin. Effects of the D257/D385A and FAD-linked mutations. Ann NY Acad Sci 2000; 920: 227-232.
30. Gantier R, Gilbert D, Dumanchin C, Campion D, Davoust D, Toma F et al. The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3β. Neurosci Lett 2000; 283: 217-220.
31. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
32. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-1668.
33. Sheldahl LC, Park M, Malbon CC, Moon RT. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol 1999; 9: 695-698.
34. Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV. Acetylcholinesterase-amyloid-β-peptide interaction and Wnt signaling involvement in Aβ neurotoxicity. Acta Neurol Scand Suppl 2000; 176: 53-59.
35. Alvarez A, Alarcón R, Opazo C, Campos EO, Muñoz FJ, Calderón FH et al. Stable complexes involving acetylcholinesterase and amyloid-β peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 1998; 18: 3213-3223.
36. Banker GA, Cowan WM. Rat hippocampal neurons in dispersed cell culture. Brain Res 1977; 126: 397-442.
37. Calderón FH, von Bernhardi R, De Ferrari GV, Luza S, Aldunate R, Inestrosa NC. Toxic effects of acetylcholinesterase on neuronal and glial-like cells in vitro. Mol Psychiatry 1998; 3: 247-255.
38. Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3β by insulin and Wnt signaling. J Biol Chem 2000; 275: 32 475-32 481.
39. García-Huidobro T, Valenzuela E, Leisewitz AV, Valderrama J, Bronfman M. Anti-proliferative effect of two novel palmitoylcarnitine analogs selective inhibitors of protein kinase C conventional isoenzymes. Eur J Biochem 1999; 266: 855-864.
40. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Meth 1984; 11: 47-60.
41. Côté SL, Ribeiro-Da-Silva A, Cuello AC. In: Cuello AC (ed). Immunocytochemistry II. John Wiley & Sons Ltd.: UK, 1993.
42. Goode N, Hughes K, Woodgett JR, Parker PJ. Differential regulation of glycogen synthase kinase-3β by protein kinase C isotypes. J Biol Chem 1992; 267: 16 878-16 882.
43. Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3β by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 1993; 296: 15-19.
44. Patapoutian A, Reichardt LF. Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol 2000; 10: 392-399.
45. Lako M, Lindsay S, Bullen P, Wilson DI, Robson SC, Strachan T. A novel mammalian wnt gene WNT8B shows brain-restricted expression in early development, with sharply delimited expression boundaries in the developing forebrain. Hum Mol Genet 1998; 7: 813-822.
46. Lee SM, Tole S, Grove E, McMahon AP. A local Wnt-3a signal is required for development of the mammalian hippocampus. Development 2000; 127: 457-467.
47. O'Hare E, Weldon DT, Mantyh PW, Ghilardi JR, Finke MP, Kuskowski MA et al. Delayed behavioral effects following intrahippocampal injection of aggregated Aβ (1-42). Brain Res 1999; 815: 1-10.
48. Chambers CB, Sigurdsson EM, Hejna MJ, Lorens SA, Lee JM, Muma NA. Amyloid-β injection in rat amygdala alters τ protein but not mRNA expression. Exp Neurol 2000; 162: 158-170.
49. Pascual T, González JL. A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Brain Res 1995; 695: 289-292.
50. Yamada K, Tanaka T, Han D, Senzaki K, Kameyama T, Nabeshima T. Protective effects of idebenone and α-tocopherol on β-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 1999; 11: 83-90.
51. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
52. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985.
53. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein τ by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 1994; 4: 1077-1086.
54. Sperber BR, Leight S, Goedert M, Lee VM. Glycogen synthase kinase-3β phosphorylates τ protein at multiple sites in intact cells. Neurosci Lett 1995; 197: 149-153.
55. Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 1998; 252: 542-552.
56. Lucas FR, Goold RG, Gordon-Weeks PR, Salinas PC. Inhibition of GSK-3β leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci 1998; 111: 1351-1361.
57. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B et al. Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999; 58: 1010-1019.
58. Alvarez G, Muñoz-Montano JL, Satrústegui J, Avila J, Bogoñez E, Diaz-Nido J. Lithium protects cultured neurons against β-amyloid-induced neurodegeneration. FEBS Lett 1999; 453: 260-264.
59. Wei H, Leeds PR, Qian Y, Wei W, Chen R, Chuang D. β-amyloid peptide-induced death of PC12 cells and cerebellar granule cell neurons is inhibited by long-term lithium treatment. Eur J Pharmacol 2000; 392: 117-123.
60. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. NeuroReport 1998; 9: 2081-2084.
61. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-1734.
62. Muñoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J. Lithium inhibits Alzheimer's disease-like τ protein phosphorylation in neurons. FEBS Lett 1997; 411: 183-188.
63. Hong M, Chen DCR, Klein PS, Lee VM-Y. Lithium reduces τ phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 1997; 272: 25 326-25 332.
64. Lovestone S, Davis DR, Webster MT, Kaech S, Brion JP, Matus A et al. Lithium reduces τ phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol Psychiatry 1999; 45: 995-1003.
65. Berridge MJ. Cell signalling. A tale of two messengers. Nature 1993; 365: 456-459.
66. Acharya JK, Labarca P, Delgado R, Jalink K, Zuker CS. Synaptic defects and compensatory regulation of inositol metabolism in inositol polyphosphate 1-phosphatase mutants. Neuron 1998; 20: 1219-1229.
67. Chen R, Chuang D. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274: 6039-6042.
68. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear β-catenin τ hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J 2001; 20: 27-39.
69. Cole G, Dobkins KR, Hansen LA, Terry RD, Saitoh T. Decreased levels of protein kinase C in Alzheimer brain. Brain Res 1988; 452: 165-174.
70. Shimohama S, Narita M, Matsushima H, Kimura J, Kameyama M, Hagiwara M et al. Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease. Neurology 1993; 43: 1407-1413.
71. Govoni S, Bergamaschi S, Racchi M, Battaini F, Binetti G, Bianchetti A et al. Cytosol protein kinase C down regulation in fibroblasts from Alzheimer's disease patients. Neurology 1993; 43: 2581-2586.
72. Van Huynh T, Cole G, Katzman R, Huang KP, Saitoh T. Reduced protein kinase C immunoreactivity and altered protein phosphorylation in Alzheimer's disease fibroblasts. Arch Neurol 1989; 46: 1195-1199.
73. Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ et al. Activation of protein kinase C inhibits cellular production of the amyloid β-protein. J Biol Chem 1993; 268: 22 959-22 962.
74. Gabuzda D, Busciglio J, Yankner BA. Inhibition of β-amyloid production by activation of protein kinase C. J Neurochem 1993; 61: 2326-2329.
75. Favit A, Grimaldi M, Nelson TJ, Alkon DL. Alzheimer's-specific effects of soluble β-amyloid on protein kinase C-α and -γ degradation in human fibroblasts. Proc Natl Acad Sci USA 1998; 95: 5562-5567.
76. Xie J, Guo Q, Zhu H, Wooten MW, Mattson MP. Protein kinase C iota protects neural cells against apoptosis induced by amyloid β-peptide. Brain Res Mol Brain Res 2000; 82: 107-113.
77. Ma W, Zheng WH, Belanger S, Kar S, Quirion R. Effects of amyloid peptides on cell viability and expression of neuropeptides in cultured rat dorsal root ganglion neurons: a role for free radicals and protein kinase C. Eur J Neurosci 2001; 13: 1125-1135.
78. Chang JT, Esumi N, Moore K, Li Y, Zhang S, Chew C et al. Cloning and characterization of a secreted frizzled-related protein that is expressed by the retinal pigment epithelium. Hum Mol Genet 1999; 8: 575-583.
79. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000; 290: 2302-2303.
80. Arheden K, Mandahl N, Strombeck B, Isaksson M, Mitelman F. Chromosome localization of the human oncogane INT1 to 12q13 by in situ hybridization. Cytogenet Cell Genet 1988; 47: 86-87.
81. Bui TD, Rankin J, Smith K, Huguet EL, Ruben S, Strachan T et al. A novel human Wnt gene, WNT10B, maps to 12q13 and is expressed in human breast carcinomas. Oncogene 1997; 13: 1249-1253.
82. Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997; 278: 1237-1241.
83. Rogaeva E, Premkumar S, Song Y, Sorbi S, Brindle N, Paterson A et al. Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. JAMA 1998; 280: 614-618.
84. Brown SD, Twells RC, Hey PJ, Cox RD, Levy ER, Soderman AR et al. Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem Biophys Res Commun 1998; 248: 879-888.
85. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000; 407: 530-535.
86. Mayeux R, Lee JH, Romas SN, Mayo D, Santana V, Williamson J et al. Chromosome-12 mapping of late-onset Alzheimer disease among Caribbean Hispanics. Am J Hum Genet 2002; 70: 237-243.